ความชุกการติดเชื้อ Human Papillomavirus ชนิดความเสี่ยงสูง และความผิดปกติของปากมดลูก ในผู้หญิงไทยที่เข้ารับการตรวจคัดกรองมะเร็งปากมดลูกที่สถาบันมะเร็งแห่งชาติ

Kanda Seeda; Chonticha  Tipmed; Pattama  Ploysawang; Parinda  Pangmuang

Authors

Kanda Seeda Department of policy development and medical strategy, National Cancer Institute, Thailand
Chonticha Tipmed Department of policy development and medical strategy, National Cancer Institute, Thailand
Pattama Ploysawang Department of policy development and medical strategy, National Cancer Institute, Thailand
Parinda Pangmuang Department of policy development and medical strategy, National Cancer Institute, Thailand

Keywords:

cervical cancer screening, HR-HPV, HPV DNA test, cervical abnormalities

Abstract

Currently, medical studies have confirmed that cervical infection by high-risk Human Papillomavirus types (HR-HPV) is a major cause of cervical cancer. Based on this knowledge, there are two strategies to help prevent cervical cancer: The first strategy is primary prevention through HPV vaccination, and the second strategy is secondary prevention through HPV testing. The current study aimed to assess the prevalence of HR-HPV infection and cervical abnormalities among women screened at National Cancer Institute. This retrospective cross-sectional descriptive study collected data from recipients who underwent cervical cancer screening at National Cancer Institute between October 1, 2021, and September 30, 2022. The data was collected from 1,549 women with a mean age of 38.02±9.93 years, 9.49% (147/1,549) were positive for HR-HPV. Among them, 1.94% (30/1,549) were infected with HPV type 16, 0.97% (15/1,549) were infected with HPV type 18, and 6.58% (102/1,549) were infected with other HP-HPV types. For colposcopy with biopsy diagnosis, 0.65% (10/1,549) were diagnosed with cervical intraepithelial neoplasia II/ III (CIN II/III). In age group analysis, women aged under 30 years had the highest prevalence of HR-HPV infection, abnormal cervical cytology (liquid based cytology; LBC) and abnormal cervical pathology compared to those other age groups. This finding may serve as preliminary data for designing studies on cervical screening guideline adjustments and establishing preventive strategies for cervical cancer in Thailand.

References

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol 1999;189(1):12-9.

Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med 2009; 361(3):271-78.

Srisomboon J. Application of HPV testing and genotyping in clinical practice [Internet]. Chiang Mai: Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University; 2010 [cited 2024 Oct 3]. Available from: https://w1.med.cmu.ac.th/obgyn/lecturestopics/residents-fellows/1531/ (in Thai)

Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and metaanalysis of non-randomized studies. J Gynecol Oncol 2007;104(1):232-46.

Termrungruanglert W, Khemapech N, Tantitamit T, Sangrajrang S, Havanond P, Laowahutanont P. Cost-effectiveness analysis study of HPV testing as a primary cervical cancer screening in Thailand. Gynecol. Oncol. Rep. 2017;22:58–63.

National Health Security Board. Annex to the announcement of the National Health Security Board on the types and scope of public health services, No. 10, B.E. 2559 (2016), pp. 19–20. (in Thai)

National Cancer Institute, Department of Medical Services. Guidelines for cervical cancer screening (HPV DNA test), fiscal year 2023 [Internet]. [cited 2024 Nov 30]. Available from: https://www.nci.go.th/th/screening01.html (in Thai)

Swangvaree SS, Kongkaew P, Rugsuj P, Saruk O. Prevalence of high-risk Human Papillomavirus infection and cytologic result in Thailand. APJCP 2010;11:1465–68.

Fongmoon D, Nakong M, Lalitwongsa S, Keyurawong W. Prevalence and distribution of high-risk human papillomavirus infection in Lampang Cancer Hospital. Chiang Mai Med Tech J. 2015;48:231–40. (in Thai)

Tangitgamol S, Kantathavorn N, Kittisiam T, Chaowaeanit W, Phoolcharoen N, Manusirivithay S, et al. Prevalence and associated factors of abnormal cervical cytology and high-risk HPV DNA among Bangkok metropolitan women. APJCP 2016;17:3147–53.

Tangsriwattana T, Phonampaisathit S, Chainuan A, Boonsom K, Wityanand T, Thijak S, et al. Prevalence and genotypes of human papillomavirus (HPV) infection in Thai women with normal Pap smear results. J Dep Med Sci. 2019;61:73–85. (in Thai)

Phetphichai S, Klaiklueng N, Boonkong A. Evaluation of the effectiveness of detecting Human Papillomavirus 14 high-risk types using Real-Time PCR in combination with cytology and colposcopy. J Med Tech. 2022;50:8067–79. (in Thai)

National Health Security Office. Health security information system (service units) [Internet]. [cited 2024 Nov 30]. Available from: https://medata.nhso.go.th/appcenter/service/dashboard-pp-2 (in Thai)

Clarke MA, Risley C, Stewart MW, Geisinger KR, Hiser Lm, et al. Age-specific prevalence of human papillomavirus and abnormal cytology at baseline in a diverse statewide prospective cohort of individuals undergoing cervical cancer screening in Mississippi. Cancer Med 2021;10:8641–50.

Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338(7):423–8.

Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 2015;136(2):189-97.

Khuhaprema T, Attasara P, Sriplung H, Wiangnon S, Sumitsawan Y et al. Cancer in Thailand (Vol.VI 2004 - 2006). National Cancer Institute, Bangkok.; 2012.

Khuhaprema T, Attasara P, Sriplung H, Wiangnon S, Sangrajrang S. Cancer in Thailand (Vol.VII 2007 - 2009). National Cancer Institute, Bangkok.; 2013.

Imsamran W, Chaiwerawattana A, Wiangnon S, Pongnikorn D, Suwanrungrung K et al. Cancer in Thailand (Vol.VIII 2010 - 2012). National Cancer Institute, Bangkok.; 2015.

Imsamran W, Pattatang A, Supattagorn P,Chiawiriyabunya I, Namthaisong K, et al. Cancer in Thailand (Vol.IX 2013 - 2015). National Cancer Institute, Bangkok.; 2018.

Rojanamatin J, Ukranun W, Supaattagorn P, Chiawiriyabunya I, Wongsena M et al. Cancer in Thailand (Vol.X, 2016 – 2018)